SI1838698T1 - Derivati pirimidina kot agonisti gcpr - Google Patents

Derivati pirimidina kot agonisti gcpr

Info

Publication number
SI1838698T1
SI1838698T1 SI200531147T SI200531147T SI1838698T1 SI 1838698 T1 SI1838698 T1 SI 1838698T1 SI 200531147 T SI200531147 T SI 200531147T SI 200531147 T SI200531147 T SI 200531147T SI 1838698 T1 SI1838698 T1 SI 1838698T1
Authority
SI
Slovenia
Prior art keywords
pyrimidine derivatives
gpcr agonists
agonists
treatment
gpcr
Prior art date
Application number
SI200531147T
Other languages
English (en)
Slovenian (sl)
Inventor
Stuart Edward Bradley
Matthew Colin Thor Fyfe
Gerard Hugh Thomas
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of SI1838698T1 publication Critical patent/SI1838698T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SI200531147T 2004-12-31 2005-12-30 Derivati pirimidina kot agonisti gcpr SI1838698T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0428514.4A GB0428514D0 (en) 2004-12-31 2004-12-31 Compounds
EP05821785A EP1838698B1 (en) 2004-12-31 2005-12-30 Pyrimidine derivatives as gpcr agonists
PCT/GB2005/050266 WO2006070208A1 (en) 2004-12-31 2005-12-30 Pyridine, pyrimidine and pyrazine derivatives as gpcr agonists

Publications (1)

Publication Number Publication Date
SI1838698T1 true SI1838698T1 (sl) 2010-12-31

Family

ID=34179041

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200531147T SI1838698T1 (sl) 2004-12-31 2005-12-30 Derivati pirimidina kot agonisti gcpr

Country Status (9)

Country Link
US (1) US8173807B2 (https=)
EP (1) EP1838698B1 (https=)
JP (1) JP4916452B2 (https=)
AT (1) ATE479677T1 (https=)
DE (1) DE602005023343D1 (https=)
ES (1) ES2350729T3 (https=)
GB (1) GB0428514D0 (https=)
SI (1) SI1838698T1 (https=)
WO (1) WO2006070208A1 (https=)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05007485A (es) 2003-01-14 2006-01-30 Arena Pharm Inc Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
EP1910290A2 (en) * 2005-06-30 2008-04-16 Prosidion Limited Gpcr agonists
BRPI0616245A2 (pt) * 2005-09-16 2011-06-14 Arena Pharm Inc modulador de metabolismo, seus usos, composiÇço farmaceutica compreendendo o mesmo, bem como mÉtodo para produÇço da referida composiÇço
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
SG10201404220TA (en) 2006-04-11 2014-10-30 Arena Pharm Inc Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
EP2112880A4 (en) 2006-12-14 2011-12-21 Merck Sharp & Dohme ACYLBIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND TREATMENT METHOD
US20100048632A1 (en) 2007-01-04 2010-02-25 Matthew Colin Thor Fyfe Piperidine GPCR Agonists
EA016507B1 (ru) 2007-01-04 2012-05-30 Прозидион Лимитед Пиперидиновые агонисты gpcr
PE20081849A1 (es) 2007-01-04 2009-01-26 Prosidion Ltd Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
CL2008000018A1 (es) 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
JP2010539152A (ja) 2007-09-10 2010-12-16 プロシディオン・リミテッド 代謝障害の治療のための化合物
RU2443699C2 (ru) 2007-09-20 2012-02-27 Айрм Ллк Соединения и композиции в качестве модуляторов активности gpr119
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
WO2009106565A1 (en) * 2008-02-27 2009-09-03 Biovitrum Ab (Publ) Agonists of gpr119
WO2009106561A1 (en) * 2008-02-27 2009-09-03 Biovitrum Ab (Publ) Pyrazine compounds for treating gpr119 related disorders
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
EP2300427A1 (en) * 2008-05-05 2011-03-30 Amgen Inc. Urea compounds as gamma secretase modulators
WO2010084512A1 (en) 2008-12-24 2010-07-29 Cadila Healthcare Limited Novel oxime derivatives
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
EA201200046A1 (ru) 2009-06-24 2012-08-30 Бёрингер Ингельхайм Интернациональ Гмбх Новые соединения, фармацевтическая композиция и связанные с ними способы
US8481731B2 (en) 2009-06-24 2013-07-09 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
JP2013522279A (ja) 2010-03-18 2013-06-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ
GB201006167D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB201006166D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
WO2012025811A1 (en) 2010-08-23 2012-03-01 Lupin Limited Indolylpyrimidines as modulators of gpr119
PH12013500547A1 (en) 2010-09-22 2013-06-10 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
KR101563793B1 (ko) 2010-10-08 2015-10-27 카딜라 핼쓰캐어 리미티드 신규한 ｇｐｒ 119 작용물질
GB201114389D0 (en) 2011-08-22 2011-10-05 Prosidion Ltd Novel compounds
AR083904A1 (es) 2010-11-18 2013-04-10 Prosidion Ltd Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos
US9000175B2 (en) 2010-11-26 2015-04-07 Lupin Limited Bicyclic GPR119 modulators
CN103635472B (zh) 2011-02-28 2018-01-12 阵列生物制药公司 丝氨酸/苏氨酸激酶抑制剂
JP6097289B2 (ja) 2011-08-04 2017-03-15 アレイ バイオファーマ、インコーポレイテッド セリン／スレオニンキナーゼインヒビターとしてのキナゾリン化合物
HUE053994T2 (hu) 2012-03-01 2021-08-30 Array Biopharma Inc Szerin/treonin kináz inhibitorok
WO2014016191A1 (en) 2012-07-24 2014-01-30 Boehringer Ingelheim International Gmbh N-cyclopropyl-n-piperidinyl-amide derivatives and their use as gpr119 modulators
AR092253A1 (es) 2012-08-27 2015-04-08 Array Biopharma Inc Inhibidores de serina/treonina cinasa
MX386419B (es) 2015-01-06 2025-03-18 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
EP3939965A1 (en) 2015-06-22 2022-01-19 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
ES2987794T3 (es) 2018-06-06 2024-11-18 Arena Pharm Inc Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
TW202115024A (zh) 2019-08-14 2021-04-16 美商英塞特公司 作為cdk2 抑制劑之咪唑基嘧啶基胺化合物
AU2020364007A1 (en) 2019-10-11 2022-04-28 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629325A (en) * 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
WO1998040356A1 (en) * 1997-03-12 1998-09-17 Banyu Pharmaceutical Co., Ltd. Drugs containing aminopyridine derivatives as the active ingredient
GB0014022D0 (en) * 2000-06-08 2000-08-02 Novartis Ag Organic compounds
US20030022891A1 (en) * 2000-12-01 2003-01-30 Anandan Palani MCH antagonists and their use in the treatment of obesity
IL157253A0 (en) 2001-02-28 2004-02-19 Merck & Co Inc Acylated piperidine derivatives as melanocortin-4 receptor agonists
DE60215132T2 (de) * 2001-02-28 2007-08-23 Merck & Co., Inc. Acylierte piperidin-derivate als melanocortin-4-rezeptor-agonisten
CA2461363A1 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
TWI330183B (https=) * 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
GB0203778D0 (en) * 2002-02-18 2002-04-03 Glaxo Group Ltd Compounds
SE0203654D0 (sv) * 2002-12-09 2002-12-09 Astrazeneca Ab New compounds
MXPA05007485A (es) * 2003-01-14 2006-01-30 Arena Pharm Inc Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
CA2530389A1 (en) * 2003-07-02 2005-01-13 Biofocus Discovery Limited Pyrazine and pyridine derivatives as rho kinase inhibitors
JP4958560B2 (ja) * 2003-12-24 2012-06-20 プロシディオン・リミテッド Ｇｐｃｒ受容体作動薬としてのヘテロ環誘導体

Also Published As

Publication number Publication date
EP1838698B1 (en) 2010-09-01
JP4916452B2 (ja) 2012-04-11
DE602005023343D1 (de) 2010-10-14
ES2350729T3 (es) 2011-01-26
WO2006070208A8 (en) 2006-08-10
EP1838698A1 (en) 2007-10-03
WO2006070208A1 (en) 2006-07-06
US20100035897A1 (en) 2010-02-11
JP2008526724A (ja) 2008-07-24
ATE479677T1 (de) 2010-09-15
GB0428514D0 (en) 2005-02-09
US8173807B2 (en) 2012-05-08

Similar Documents

Publication Publication Date Title
SI1838698T1 (sl) Derivati pirimidina kot agonisti gcpr
TNSN08407A1 (en) Organic compounds
MX2009003972A (es) Compuesto de indol.
UA81468C2 (en) Heteroarylcarbamoylbenzene derivatives
TW200732306A (en) Pyrimidine derivatives
MX2009010246A (es) Derivados de 8-oxi-quinolina como moduladores del receptor bradiquinina b2.
DK1585739T3 (da) Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer
NO20070122L (no) Quinazolinonderivater anvendelige som vanilloidantagonister
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
WO2005074643A3 (en) Benzamide compounds useful as rock inhibitors
MX2007005694A (es) Nuevos derivados de betulina, preparacion y uso de los mismos.
MY147211A (en) Novel dihydropseudoerythromycin derivatives
EP2141214A3 (en) Novel organic electroluminescent compounds and organic electroluminescent device using the same
JO2681B1 (en) Indole derivatives
AR064735A1 (es) Agonistas de gpcr y composicion farmaceutica en base al compuesto
WO2008051533A3 (en) Benzimidazole compounds
GEP20125571B (en) Pyrrolidin-2-one derivatives as androgen receptor modulators
MY163114A (en) Cyclopentylacrylamide derivative
MX2008013520A (es) Agonistas del receptor de adenosina a3.
MY152475A (en) Fused ring compounds and use thereof
TW200628153A (en) Novel compounds
MX2007003911A (es) Derivados y usos de benzoxazina y quinoxalina.
NO20062965L (no) NK-1-Reseptorantagonister
MX2010007632A (es) Composicion farmaceutica estable.
TH105091A (th) อะโกนิสต์ของ gpcr